Baird Starts Idenix Pharmaceuticals Inc. (IDIX) at Neutral; No Great Pipeline but Patents Could Have Value
Tweet Send to a Friend
After the close, Baird initiated coverage on Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) with a Neutral and $5 price tarrget.
This article: 112 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 112 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
